AMLX (Amylyx Pharmaceuticals) EBIT: $-159.27 Mil (TTM As of Mar. 2026)

What is Amylyx Pharmaceuticals EBIT?

Amylyx Pharmaceuticals AMLX +2.59% 33 EBIT is $-159.27 Mil as of Mar. 2026. GuruFocus rates AMLX with a GF Score™ of 33/100. The stock has 2 warning signs investors should review.

Amylyx Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-43.78 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-159.27 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Amylyx Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2026 was -1,054.34%. Amylyx Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -3,309.07%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Amylyx Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -9.57%.

Amylyx Pharmaceuticals (NAS:AMLX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Amylyx Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-175.116 * ( 1 - 0% )	/	( (20.288	+	12.93)	/ 2 )
=	-175.116	/	16.609
=	-1,054.34 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	332.645	-	11.374	-	( 316.979	-	max(0, 22.688	-	323.671	+	316.979	))
=	20.288

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	293.603	-	11.615	-	( 279.768	-	max(0, 15.966	-	285.024	+	279.768	))
=	12.93

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Amylyx Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-175.116	/	( ( (5.491 + max(-14.737, 0))	+	(5.093 + max(-9.555, 0)) )	/	2 )
=	-175.116	/	( ( 5.491	+	5.093 )	/	2 )
=	-175.116	/	5.292
=	-3,309.07 %

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.088	+	0	+	6.604)	-	(11.374	+	0	+	10.055)
=	-14.737

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	5.256)	-	(11.615	+	0	+	3.196)
=	-9.555

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Amylyx Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2026 )
	=	-159.268	/	1664.952
	=	-9.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amylyx Pharmaceuticals EBIT Related Terms

Amylyx Pharmaceuticals EBIT Historical Data

* Premium members only.

The historical data trend for Amylyx Pharmaceuticals's EBIT can be seen below:

Amylyx Pharmaceuticals EBIT Chart

Amylyx Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

-82.69

-201.34

38.80

-255.68

-153.29

Amylyx Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT	Get a 7-Day Free Trial															-37.80	-42.86	-36.03	-36.61	-43.78

AMLX vs PRGO, ANIP, HROW: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Amylyx Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amylyx Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amylyx Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Amylyx Pharmaceuticals's EV-to-EBIT falls into.

Save Embed

33GF Score

Amylyx Pharmaceuticals Inc AMLX

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Amylyx Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-159.27 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-159.27 Mil mean?

Amylyx Pharmaceuticals (AMLX) has a EBIT of $-159.27 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Amylyx Pharmaceuticals.

Is Amylyx Pharmaceuticals' EBIT too high?

Amylyx Pharmaceuticals' current EBIT is $-159.27 Mil. Overall, Amylyx Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.

How does Amylyx Pharmaceuticals' EBIT compare to PRGO and ANIP?

Amylyx Pharmaceuticals' EBIT of $-159.27 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Drug Manufacturers company?

A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Amylyx Pharmaceuticals. Amylyx Pharmaceuticals's current EBIT is $-159.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Amylyx Pharmaceuticals stock overvalued right now?

Amylyx Pharmaceuticals (AMLX) has a current EBIT of $-159.27 Mil. The current EBIT is $-159.27 Mil. Amylyx Pharmaceuticals' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Amylyx Pharmaceuticals (AMLX), the current EBIT is $-159.27 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Amylyx Pharmaceuticals Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies PRGO ANIP HROW PAHC COLL XERS ALVO PBH BCRX PCRX XTER:MRK TSE:4502 XSWX:GALD SHSE:600276 NSE:SUNPHARMA XTAE:TEVA LSE:HLN XSWX:SDZ ZTS HKSE:03692

Address 55 Cambridge Parkway, Suite 6W, Cambridge, MA, USA, 02142

Website https://www.amylyx.com

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.

33GF Score

Get the complete analysis for AMLX

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.44

Price

View AMLX Analysis

See EBIT data for all stocks →